Table 2

 Comparison of features from longitudinal clinic data and drug trials of psoriatic arthritis (PsA)

PsA Clinic17*Trials
Sulfasalazine29Leflunomide30Etanercept 231Etanercept 332Infliximab 233Infliximab 334
*Updated information from the University of Toronto PsA Clinic.
CRP, C-reactive protein; ESR, erythrocyte sedimentation rate; HAQ, Health Assessment Questionnaire; NA, not available.
Demographic features
    No of patients65022119060205102200
    Duration of psoriasis14.619.51819NANA
    Duration of arthritis7.51210.5109165.4
    Age at first visit (years)43.5504845474647
Clinical features
    No of patients65022119060205102200
    No of tender joints10131920NA2023
    No of swollen joints3NA1214NA1312
Acute phase reactants and health status
    No of patients34922119060205102200
    Mean ESR/CRPNANA18/1.3NA30/6NA